尼莫地平对胰腺疾病患者血胰屏障通透性的影响

EFFECTS OF NIMODIPINE ON BLOOD PANCREATIC BARRIER PENETRANCE IN PATIENTS WITH PANCREATIC DISEASES

为探讨尼莫地平对胰腺疾病患者血胰屏障通透性的影响，采用反相高压液相色谱法对１５例胰腺疾病患者在口服尼莫地平后不同时段胰液标本中的尼莫地平浓度进行了检测。结果：在用药后０．５、１、１．５、２、２．５、３、３．５和４小时，该１５例受试者胰液中的尼莫地平平均浓度分别为４．７９、７．３１、９．２１、８．０４、６．０５、５．１１、３．３７和１．１９ｎｇ／ｍｌ；尼莫地平的胰液浓度高峰时间为用药后１．５～２小时，最高浓度为９．２１ｎｇ／ｍｌ。由此提示尼莫地平可以穿透血胰屏障。

To survey the penetrance of Nimodipine to blood pancreatic barrier. Pancreatic fluid of 15 cases with pancreatic diseases were respectively sampled from pancreatic drainage tubes at different time after Nimodipine taken orally, and the concentrations of Nimodipine in the fluid were measured with high performance liquid chromatography (HPLC). The average concentration of Nimodipine in pancreatic fluid at 0.5,1,1.5,2,2.5,3,3.5,4 hours after Nimodipine administration were 4.79, 7.31 ,9.21,8.04,6.05,5.11,3.37 and 1.19 ng/ml, respectively. The highest value of Nimodipine level in pancreatic fluid were 9.21 ng/ml at 1.5 to 2 hours following Nimodipine taken orally. These suggested that the Nimodipine can penetrate across the blood pancreatic barrier and make its pharmacolohical effect in pancreatic tissue.